Edison new valuation Targovax 24,90 NOK
13.06.2018 kl 11:25 2171
Dette er en arkivert tråd!
On 12 June, Targovax announced a strategic decision to move away from developing TG01, a neoantigen cancer vaccine for pancreatic cancer after new data with FOLFIRINOX set the bar for overall survival too high. With median overall survival of pancreatic cancer patients approaching five years, such a long clinical trial is beyond the capabilities of a relatively small biotech company, according to Targovax. We have removed pancreatic cancer from our valuation, which is now NOK1.31bn or NOK24.9/share (vs NOK33.8/share previously).
Redigert 13.06.2018 kl 11:27 Arkivert